DTU
DTU

Professor Rury Holman

Picture of Rury Holman Highly Cited Researcher

Position:Emeritus Director

PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240

Email:rury.holman@dtu.ox.ac.uk

ORCID ID0000-0002-1256-874X

Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.

Latest publications

Manuscript
Sex differences in complications, care, and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Jennifer B. Green et al.
Diabetes Obes Metab. 2023

Manuscript
Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials
Ernesto Maddaloni et al.
Diabetes Obes Metab. 2023

Manuscript
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial
Abderrahim Oulhaj et al.
Diabetes Obes Metab. 2023

Manuscript
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study
Beverley M. Shields et al.
Nature Medicine 2022

Manuscript
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
Beverley M. Shields et al.
Nature Medicine 2022

Manuscript
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study
John M Dennis et al.
Lancet Digit Health 2022;4:e873-83